Cardiogen
Khavinson cardiovascular short-peptide bioregulator
Overview
Cardiogen is a Khavinson-class short-peptide bioregulator positioned as the cardiovascular-tissue member of the Khavinson short-peptide framework. Like the other Khavinson products, Cardiogen is hypothesized to act as an endogenous bioregulator of gene-expression programs in its target tissue (cardiomyocytes and cardiovascular tissue), supporting cell-cycle balance and tissue maintenance under stress. The molecule appears in the Russian and Eastern European research literature as part of the broader Khavinson bioregulator class but does not carry a single defined sequence in all sources, buyers should treat Cardiogen as a class designation requiring batch-specific identity confirmation rather than a single defined molecule. Lyochem supplies Cardiogen as a lyophilized 20 mg vial at ≥99.0% HPLC purity. As with the rest of the Khavinson class, CAS is not consistently registered and identity must be established via sequence verification on the batch COA. Buyers conducting research-protocol work involving Cardiogen should request the exact sequence on the COA and confirm it matches the published reference they are working from.
Who buys this, and why
Khavinson short bioregulators — Admax, Cortagen, Cartalax, Cardiogen, Bronchogen, Crystagen, Prostamax, Vesugen — ship to research labs replicating Russian-school protocols or running comparative tissue-specific peptide-bioregulator studies. The published literature base for this class is concentrated in Russian-language sources; buyers should expect to consult that literature directly for protocol selection. Analytical-packet expectations are the same as any other lyophilised research peptide.
Primary buyer fit: academic and contract research laboratories.
Specifications
- CAS
- (verification pending, please confirm via COA)
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 20 mg
- MOQ
- On request
- Lead time
- 14–21 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Source-literature pointer (Russian-language references on request)
- Stability at −20 °C across 12 months
- Sequence ladder available on request
Regulatory note
Khavinson bioregulator; CAS commonly not registered. Confirm sequence and identity per batch COA.
Frequently asked questions
Is there published clinical evidence supporting Cardiogen for cardiovascular indications?▾
Cardiogen is positioned within the Khavinson short-peptide bioregulator framework as the cardiovascular-tissue regulatory peptide, but the published clinical evidence is concentrated in Russian and Eastern European journals with limited Western peer-reviewed coverage. The Russian-school literature reports cardiovascular-protective effects in animal models and small clinical cohorts, but the methodology and statistical power of these studies don't meet the rigor standards of Western evidence-based-medicine frameworks. Buyers conducting Cardiogen research should reference the original Khavinson-school publications for protocol design and treat the molecule as an investigational research tool rather than a clinically-validated cardiovascular agent.
How does Cardiogen relate to Vesugen within the cardiovascular branch of the Khavinson framework?▾
Cardiogen and Vesugen are positioned as complementary cardiovascular-tissue regulatory peptides within the broader Khavinson framework. Cardiogen targets cardiomyocyte and myocardial-tissue gene-expression programs; Vesugen (KED tripeptide) targets vascular endothelial gene-expression. The two peptides are sometimes combined in cardiovascular-research protocols on the rationale that comprehensive cardiovascular effects involve both myocardium and vasculature. As with all Khavinson-class products, the comparative pharmacology is concentrated in the Russian-school literature and the mechanistic distinction between the two peptides isn't supported by independent Western data. Buyers conducting comparative research should source both products and reference the original Khavinson publications for protocol design specifics.
What sequence does Cardiogen actually have, and why is the specification ambiguous?▾
Unlike the well-characterized tetrapeptide members of the Khavinson family (Epitalon AEDG, Bronchogen AEDL, Cortagen AEDP), Cardiogen's exact peptide sequence is not consistently published in primary Khavinson-school sources, and different upstream suppliers may produce somewhat different preparations under the Cardiogen brand name. Some sources describe Cardiogen as a tetrapeptide; others position it as a small mixture of cardiovascular-targeting short peptides. The sequence ambiguity is the primary reason CAS is not registered and why batch-COA sequence-verification is essential before any research use, buyers should request the explicit sequence on the released batch documentation and treat Cardiogen as a defined product only after that confirmation.
Related peptides
Buyers who view Cardiogen also ask about:
4-mer
Bronchogen
≥99.0%Khavinson bioregulator tetrapeptide (Ala-Glu-Asp-Leu, AEDL)
- CAS
- —
- Vial
- 20 mg
4-mer
Cortagen
≥99.0%Khavinson cortical bioregulator tetrapeptide (Ala-Glu-Asp-Pro, AEDP)
- CAS
- —
- Vial
- 20 mg
3-mer
Vesugen
≥99.0%Khavinson vascular tripeptide (Lys-Glu-Asp, KED)
- CAS
- —
- Vial
- 10 mg